chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 12.0
Sex: M
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 21-OCT-2022, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several cases received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 11.0
Sex: M
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 27-SEP-2022, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome, Smear cervix abnormal, Urinary tract infection
Clinical narrative: ADULT OBSTRUCTIVE SLEEP APNEA 2/26/2022 ABNL CERVICAL PAP ADULT OBSTRUCTIVE SLEEP APNEA 2/26/2022 UTI (URINARY TRACT INFECTION)
Age: 0.58
Sex: M
Vaccine: COVID19-2
Symptoms: Underdose
Clinical narrative: Incorrect Moderna bivalent formula administered as first dose in the COVID-19 series for an unvaccinated 7 month-old infant.  0.2mL (10micrograms) of Moderna bivalent formula in a marron cap and yellow label administered as a first dose in the COVID-19 series.  Previous to April 18, 2023, this formula was designated as bivalent formula for the age group of 6month - 5 year old child.  However, with the new guidance, dose 1 of the Moderna COVID-19 series for an unvaccinated 7 month old infant, now requires 0.25mL Blue cap and Gray label Bivalent Moderna Formula (that was previously only designated for 6years+).
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Anaemia, Aortic aneurysm, Dyspnoea, Hypoxia
Clinical narrative: J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ANEMIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ANEMIA J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ANEMIA R09.02 HYPOXIA 5/14/2022 ANEMIA J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ANEMIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ANEMIA J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ANEMIA R09.02 HYPOXIA 5/14/2022 ANEMIA J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 SHORTNESS OF BREATH J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 SHORTNESS OF BREATH J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 SHORTNESS OF BREATH R09.02 HYPOXIA 5/14/2022 SHORTNESS OF BREATH J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART R09.02 HYPOXIA 5/14/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 PNEUMONIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 PNEUMONIA J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 PNEUMONIA R09.02 HYPOXIA 5/14/2022 PNEUMONIA J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 RECTAL BLEEDING J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 RECTAL BLEEDING J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 RECTAL BLEEDING R09.02 HYPOXIA 5/14/2022 RECTAL BLEEDING J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ACUTE RESPIRATORY FAILURE J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ACUTE RESPIRATORY FAILURE J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ACUTE RESPIRATORY FAILURE R09.02 HYPOXIA 5/14/2022 ACUTE RESPIRATORY FAILURE J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 PNEUMONIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 PNEUMONIA J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 PNEUMONIA R09.02 HYPOXIA 5/14/2022 PNEUMONIA J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE R09.02 HYPOXIA 5/14/2022 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ACUTE RESPIRATORY FAILURE J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ACUTE RESPIRATORY FAILURE J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ACUTE RESPIRATORY FAILURE R09.02 HYPOXIA 5/14/2022 ACUTE RESPIRATORY FAILURE
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Pneumonia, Rectal haemorrhage, Respiratory failure
Clinical narrative: J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ANEMIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ANEMIA J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ANEMIA R09.02 HYPOXIA 5/14/2022 ANEMIA J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ANEMIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ANEMIA J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ANEMIA R09.02 HYPOXIA 5/14/2022 ANEMIA J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 SHORTNESS OF BREATH J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 SHORTNESS OF BREATH J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 SHORTNESS OF BREATH R09.02 HYPOXIA 5/14/2022 SHORTNESS OF BREATH J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART R09.02 HYPOXIA 5/14/2022 ABDOMINAL AORTIC ANEURYSM, UNSPECIFIED PART J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 PNEUMONIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 PNEUMONIA J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 PNEUMONIA R09.02 HYPOXIA 5/14/2022 PNEUMONIA J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 RECTAL BLEEDING J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 RECTAL BLEEDING J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 RECTAL BLEEDING R09.02 HYPOXIA 5/14/2022 RECTAL BLEEDING J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ACUTE RESPIRATORY FAILURE J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ACUTE RESPIRATORY FAILURE J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ACUTE RESPIRATORY FAILURE R09.02 HYPOXIA 5/14/2022 ACUTE RESPIRATORY FAILURE J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 PNEUMONIA J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 PNEUMONIA J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 PNEUMONIA R09.02 HYPOXIA 5/14/2022 PNEUMONIA J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE R09.02 HYPOXIA 5/14/2022 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE J96.00 ACUTE RESPIRATORY FAILURE 6/5/2022 ACUTE RESPIRATORY FAILURE J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 5/14/2022 ACUTE RESPIRATORY FAILURE J96.21 ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE 6/6/2022 ACUTE RESPIRATORY FAILURE R09.02 HYPOXIA 5/14/2022 ACUTE RESPIRATORY FAILURE
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chills, Pyrexia, Rhinorrhoea, SARS-CoV-2 test positive
Clinical narrative: I tested positive for COVID-19 on March 13, 2023. My symptoms were fever, chills, runny nose and I was prescribed Paxlovid for my symptoms.
Age: 17.0
Sex: F
Vaccine: MENB
Symptoms: Asthenia, Decreased appetite, Fatigue, Headache, Malaise
Clinical narrative: Per parent report: Pt. became ill for about a week, feeling fatigue/drowsy, HA, no energy, loss of appetite and her HA turned into a migraine that lasted about 6 weeks
Age: 17.0
Sex: F
Vaccine: MENB
Symptoms: Migraine, Somnolence
Clinical narrative: Per parent report: Pt. became ill for about a week, feeling fatigue/drowsy, HA, no energy, loss of appetite and her HA turned into a migraine that lasted about 6 weeks
Age: 50.0
Sex: M
Vaccine: COVID19-2
Symptoms: Asthenia, COVID-19, Cough, Decreased appetite, Diarrhoea
Clinical narrative: On 5/8/2023, I came to work feeling a little warm and little bit queasy. I drank more water than usual, because I hoped it would make me feel better. It didn't really help, though. I just felt off-kilter, and I thought that it was probably allergies causing it. I went home after work that day and took some Tylenol and lay down. I woke up about two hours later at around 6:30 PM. I still didn't feel well, and I thought it would probably be a good idea to take a COVID-19 test. I took a home antigen test and very quickly got a positive result. I informed my boss and messaged my doctor and then went to bed. When I woke up the morning of 5/9/2023, I had headache, runny nose, dry cough, mild muscle aches, and diarrhea. I went to the bathroom upon waking up and then went back to bed. I then saw on my phone that my doctor had tried to reach me. She left me a message informing me that she had prescribed me Paxlovid, which I began taking the evening of 5/9/2023. Ever since then, I have been sleeping a lot, drinking plenty of water, and trying to eat a little, even though I haven't had much of an appetite. Today is the first time that I have felt significantly better since getting sick. I don't feel as weak. I slept ten hours last night, which was an improvement, because I have lately been able to sleep only around two or three hours at a time. My appetite came back today. I ate an entire steak and was able to keep it down. I still sometimes get diarrhea, though it's not as frequent now as it was at the beginning. Whenever I make bowel movements now, it's typically diarrhea rather than solid stool. I still have intermittent headaches, though they are not as frequent now. On the night of 5/8/2023, I had a fever of 102, for which I took Tylenol. When I woke up the following morning, my temperature was 99.5. On 5/9/2023 at 6:45 PM, I had a temperature of 101, which I successfully treated with Tylenol. Ever since then, my temperature has vacillated between 98.8 and 99.1. My baseline temperature is usually 97.1, so those temperatures are still above average for me.
Age: 50.0
Sex: M
Vaccine: COVID19-2
Symptoms: Feeling abnormal, Feeling hot, Headache, Hypersomnia, Insomnia
Clinical narrative: On 5/8/2023, I came to work feeling a little warm and little bit queasy. I drank more water than usual, because I hoped it would make me feel better. It didn't really help, though. I just felt off-kilter, and I thought that it was probably allergies causing it. I went home after work that day and took some Tylenol and lay down. I woke up about two hours later at around 6:30 PM. I still didn't feel well, and I thought it would probably be a good idea to take a COVID-19 test. I took a home antigen test and very quickly got a positive result. I informed my boss and messaged my doctor and then went to bed. When I woke up the morning of 5/9/2023, I had headache, runny nose, dry cough, mild muscle aches, and diarrhea. I went to the bathroom upon waking up and then went back to bed. I then saw on my phone that my doctor had tried to reach me. She left me a message informing me that she had prescribed me Paxlovid, which I began taking the evening of 5/9/2023. Ever since then, I have been sleeping a lot, drinking plenty of water, and trying to eat a little, even though I haven't had much of an appetite. Today is the first time that I have felt significantly better since getting sick. I don't feel as weak. I slept ten hours last night, which was an improvement, because I have lately been able to sleep only around two or three hours at a time. My appetite came back today. I ate an entire steak and was able to keep it down. I still sometimes get diarrhea, though it's not as frequent now as it was at the beginning. Whenever I make bowel movements now, it's typically diarrhea rather than solid stool. I still have intermittent headaches, though they are not as frequent now. On the night of 5/8/2023, I had a fever of 102, for which I took Tylenol. When I woke up the following morning, my temperature was 99.5. On 5/9/2023 at 6:45 PM, I had a temperature of 101, which I successfully treated with Tylenol. Ever since then, my temperature has vacillated between 98.8 and 99.1. My baseline temperature is usually 97.1, so those temperatures are still above average for me.
Age: 50.0
Sex: M
Vaccine: COVID19-2
Symptoms: Malaise, Myalgia, Nausea, Pyrexia, Rhinorrhoea
Clinical narrative: On 5/8/2023, I came to work feeling a little warm and little bit queasy. I drank more water than usual, because I hoped it would make me feel better. It didn't really help, though. I just felt off-kilter, and I thought that it was probably allergies causing it. I went home after work that day and took some Tylenol and lay down. I woke up about two hours later at around 6:30 PM. I still didn't feel well, and I thought it would probably be a good idea to take a COVID-19 test. I took a home antigen test and very quickly got a positive result. I informed my boss and messaged my doctor and then went to bed. When I woke up the morning of 5/9/2023, I had headache, runny nose, dry cough, mild muscle aches, and diarrhea. I went to the bathroom upon waking up and then went back to bed. I then saw on my phone that my doctor had tried to reach me. She left me a message informing me that she had prescribed me Paxlovid, which I began taking the evening of 5/9/2023. Ever since then, I have been sleeping a lot, drinking plenty of water, and trying to eat a little, even though I haven't had much of an appetite. Today is the first time that I have felt significantly better since getting sick. I don't feel as weak. I slept ten hours last night, which was an improvement, because I have lately been able to sleep only around two or three hours at a time. My appetite came back today. I ate an entire steak and was able to keep it down. I still sometimes get diarrhea, though it's not as frequent now as it was at the beginning. Whenever I make bowel movements now, it's typically diarrhea rather than solid stool. I still have intermittent headaches, though they are not as frequent now. On the night of 5/8/2023, I had a fever of 102, for which I took Tylenol. When I woke up the following morning, my temperature was 99.5. On 5/9/2023 at 6:45 PM, I had a temperature of 101, which I successfully treated with Tylenol. Ever since then, my temperature has vacillated between 98.8 and 99.1. My baseline temperature is usually 97.1, so those temperatures are still above average for me.
Age: 50.0
Sex: M
Vaccine: COVID19-2
Symptoms: SARS-CoV-2 test positive
Clinical narrative: On 5/8/2023, I came to work feeling a little warm and little bit queasy. I drank more water than usual, because I hoped it would make me feel better. It didn't really help, though. I just felt off-kilter, and I thought that it was probably allergies causing it. I went home after work that day and took some Tylenol and lay down. I woke up about two hours later at around 6:30 PM. I still didn't feel well, and I thought it would probably be a good idea to take a COVID-19 test. I took a home antigen test and very quickly got a positive result. I informed my boss and messaged my doctor and then went to bed. When I woke up the morning of 5/9/2023, I had headache, runny nose, dry cough, mild muscle aches, and diarrhea. I went to the bathroom upon waking up and then went back to bed. I then saw on my phone that my doctor had tried to reach me. She left me a message informing me that she had prescribed me Paxlovid, which I began taking the evening of 5/9/2023. Ever since then, I have been sleeping a lot, drinking plenty of water, and trying to eat a little, even though I haven't had much of an appetite. Today is the first time that I have felt significantly better since getting sick. I don't feel as weak. I slept ten hours last night, which was an improvement, because I have lately been able to sleep only around two or three hours at a time. My appetite came back today. I ate an entire steak and was able to keep it down. I still sometimes get diarrhea, though it's not as frequent now as it was at the beginning. Whenever I make bowel movements now, it's typically diarrhea rather than solid stool. I still have intermittent headaches, though they are not as frequent now. On the night of 5/8/2023, I had a fever of 102, for which I took Tylenol. When I woke up the following morning, my temperature was 99.5. On 5/9/2023 at 6:45 PM, I had a temperature of 101, which I successfully treated with Tylenol. Ever since then, my temperature has vacillated between 98.8 and 99.1. My baseline temperature is usually 97.1, so those temperatures are still above average for me.
Age: 1.25
Sex: M
Vaccine: COVID19
Symptoms: Underdose
Clinical narrative: We administered the wrong vaccine to a Pediatric patient (15 month old) we administered  Moderna pink cap product (0.2mL/10) was given instead of the blue cap product (0.25 mL/25).
Age: 57.0
Sex: F
Vaccine: VARZOS
Symptoms: Blister, Dizziness, Erythema, Induration, Nausea
Clinical narrative: pt woke with large (approximately 3in diameter) red, swollen, hot and hard spot on her arm. it appeared to have about a thumb size area in the center that looked like little blister. pt reported fever, dizzy, lightheaded and nauseous. pt counseled to apply ice 15min q3 to4 hours and take ibuprofen. pt visited dr office but only seen by nurse who seemed unconerned. pt call back 5/12 to say red area was now larger and there were more blisters.
Age: 57.0
Sex: F
Vaccine: VARZOS
Symptoms: Peripheral swelling, Pyrexia, Skin warm
Clinical narrative: pt woke with large (approximately 3in diameter) red, swollen, hot and hard spot on her arm. it appeared to have about a thumb size area in the center that looked like little blister. pt reported fever, dizzy, lightheaded and nauseous. pt counseled to apply ice 15min q3 to4 hours and take ibuprofen. pt visited dr office but only seen by nurse who seemed unconerned. pt call back 5/12 to say red area was now larger and there were more blisters.
Age: 59.0
Sex: M
Vaccine: HEPA
Symptoms: Extra dose administered, Homeless, Inappropriate schedule of product administration
Clinical narrative: Prior to vaccine administration, patient was unable to be found in system, patient was asked prior Hx of Hep A vaccination and denied prior Hep A vaccination. Patient risk factors for Hep A included homelessness. Hep A vaccine screening form completed and patient was administered a single dose of Havrix into left deltoid. No adverse reactions or side effects noted post-administration. After returning from the field, RN was able to find patient vaccination record which noted that the patient had already received 2 doses of Hepatitis A.  Dose 1: 9/20/2017, Dose 2: 1/13/2020. Third dose administered on 5/12/2023. Entered into record. Leadership was notified of incident and directed RN to comlpete VAERS form and internal incident report.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Biopsy bone marrow abnormal, Blood test abnormal, CALR gene mutation, Essential thrombocythaemia, Full blood count abnormal
Clinical narrative: New onset of severe night sweats and confirmed diagnosis of Essential Thrombocytosis with new CALR 5bp insertion gene mutation as evidenced by bloodwork and bone marrow biopsy. Earliest known evidence of significantly elevated platelet count was on 7/26/21, with count continuing to increase. Accompanied by concern of progression to myelofibrosis and/or thrombosis due to this new gene mutation following a two-dose COVID vaccination series and booster. Treatment at this time includes 81 mg aspirin daily with ongoing disease.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Hyperhidrosis, Megakaryocytes abnormal, Night sweats, Platelet count increased, Splenomegaly
Clinical narrative: New onset of severe night sweats and confirmed diagnosis of Essential Thrombocytosis with new CALR 5bp insertion gene mutation as evidenced by bloodwork and bone marrow biopsy. Earliest known evidence of significantly elevated platelet count was on 7/26/21, with count continuing to increase. Accompanied by concern of progression to myelofibrosis and/or thrombosis due to this new gene mutation following a two-dose COVID vaccination series and booster. Treatment at this time includes 81 mg aspirin daily with ongoing disease.
Age: 22.0
Sex: F
Vaccine: COVID19
Symptoms: Ultrasound abdomen abnormal
Clinical narrative: New onset of severe night sweats and confirmed diagnosis of Essential Thrombocytosis with new CALR 5bp insertion gene mutation as evidenced by bloodwork and bone marrow biopsy. Earliest known evidence of significantly elevated platelet count was on 7/26/21, with count continuing to increase. Accompanied by concern of progression to myelofibrosis and/or thrombosis due to this new gene mutation following a two-dose COVID vaccination series and booster. Treatment at this time includes 81 mg aspirin daily with ongoing disease.
Age: 14.0
Sex: F
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 23-MAR-2023, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 11.0
Sex: F
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: Medication error, No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 09-MAR-2023, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 11.0
Sex: F
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 09-MAR-2023, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 12.0
Sex: F
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: Medication error, No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 26-JAN-2023, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 12.0
Sex: F
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 26-JAN-2023, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 13.0
Sex: M
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 03-OCT-2022, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 15.0
Sex: M
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: Medication error, No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 01-JAN-2023, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 15.0
Sex: M
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 01-JAN-2023, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221:
Age: 17.0
Sex: F
Vaccine: HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9, HPV9
Symptoms: Medication error, No adverse event, Product storage error
Clinical narrative: no additional AEs reported; GARDASIL 9 were administered to multiple unknown patients following temperature excursion; This non-valid, spontaneous report was received from an office manager and referred to multiple patients of unknown age and gender. The patients' concurrent conditions, concomitant therapies and medical history was not provided.  On an unknown date, multiple patients were vaccinated with hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.On unknown dates, the doses of vaccines experienced the temperature excursions of 8.55 Celsius degrees for 8 minutes and 9.29 Celsius degrees for 12 minutes (product storage error). There were no previous excursions reported. No additional adverse event (AE) details were reported (no adverse event).  This report is non-valid due to lack of patients' identifiers.  Follow-up information was received from an office manager on 10-MAY-2023:  The patient identifiers was updated such as date of birth, address and gender.  On 28-DEC-2022, the patient was vaccinated with one dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) pre-filled syringe, injection, 1 dose, lot # and expiration dates: 1775811, 07-DEC-2023; 1775827, 27-JUN-2024; W009829, 19-OCT-2024; U032681, 26-OCT-2023; and 1780876, 09-NOV-2023 (administration sites, and routes of administration were not provided) administered for prophylaxis.  Temperature excursion total time was 25 minutes. There was 3 temperature excursions: on 09-SEP-2022 for 8 minutes, on 16-SEP-2022 for 5 minutes and on 03-JAN-2023 for 12 minutes. Excursions were not noted until after the first fact due to employee error of cleaning data logger more than once a day.  The vaccines was purhased with public and privet founds and were given in private doctor's office/ hospital.The medication error occurred in the point of storage in clinical practice.  This is one of several reports received from the same reporter. ; Sender's Comments:  US-009507513-2304USA002221: